CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Gufic BioSciences Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Gufic BioSciences Ltd
Gufic House
Sobhash Road, Vile Parle East
Phone: +91 2267261000p:+91 2267261000 MUMBAI, 400057  India Ticker: GUFICBIOGUFICBIO
This company was Merged or Acquired on 11/3/2023.
This is a Subsidiary, click here for the Parent Company
Business Summary
Gufic Biosciences Limited is an India-based company, which is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The Company operates through the pharmaceutical segment. It has pharmaceutical products under categories, such as Criti Care, including Doxific, Micafung, Rabol and Tigefic-Plus; Criticare Life, including Ticofic-200 and Gufivan-500; Ferticare, including Puregraf 75IU 3D, Cetrocare 0.25mg 3D and Follicare 150IU 3D; Spark, including Aznee Duo, Eclin, Flabone, Vipro M and Zad G; Herbal, including Bocomo-Forte, Sallaki-Liniment, Zulcer Cap and Smashit tablet, and Aesthaderm, including Prosil, Moiseta Face Wash and Revanox Serum. Its personal care products include StretchNil, Shapers-Natural Feel, Shaper-DryFeel and RollOn. Its products under active pharmaceutical ingredient (API)/bulk drugs include Micafungin, Anidulafungin, Sulconazole and Everolimus. Its Gufic Stridden includes Irvical and Eve.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20233/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2835 In vitro and in vivo diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Managing Director Jayesh P.Choksi 68 1/1/2017
Chief Executive Officer, Whole Time Director Pranav J.Choksi 3/1/2010
Chief Financial Officer Devkinandan B.Roonghta 10/1/2018 10/1/2018
8 additional Officers and Directors records available in full report.

Business Names
Business Name
509079
Gufic BioSciences Ltd
Gufic BioSciences Ltd(NDA)
Gufic BioSciences Ltd.
GUFICBIO

General Information
Number of Employees: 1,628 (As of 3/31/2023)
Outstanding Shares: 100,277,506 (As of 10/11/2023)
Shareholders: 39,563
Stock Exchange: NSE
Fax Number: +91 2267261067


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 24, 2024